Product Code Database
Example Keywords: tetris -tomtom $54-114
   » » Wiki: Tetrabenazine
Tag Wiki 'Tetrabenazine'.
Tag

Tetrabenazine is a drug for the symptomatic treatment of movement disorders. It is sold under the brand names Nitoman and Xenazine among others. On August 15, 2008, the US Food and Drug Administration (FDA) approved the use of tetrabenazine to treat chorea associated with Huntington's disease. Although other drugs had been used "", tetrabenazine was the first approved treatment for Huntington's disease in the United States. 1st US drug for Huntington's disease wins approval The compound has been known since the 1950s.


Medical uses
Tetrabenazine is used as a treatment, but not as a , for hyperkinetic disorders such as:

  • Huntington's disease – specifically, the associated with it
  • Tourette syndrome and other
  • Tardive dyskinesia, a serious and sometimes irreversible side effect of long-term use of many antipsychotics, mainly typical antipsychotics
  • , spontaneous flinging limb movements due to contra-lateral subthalamic nucleus damage

Tetrabenazine has been used as an in the treatment of , both in the past and in modern times.


Adverse effects
The most common adverse effects, which have occurred in at least 10% of subjects in studies and at least 5% greater than in subjects who received placebo, have been: sedation or somnolence, fatigue, insomnia, depression, suicidal thoughts, , anxiety, and nausea. It has also been reported to produce .


Black box warning
There is a associated with the use of tetrabenazine:

  • Increases the risk of depression and suicidal thoughts and behavior in patients with Huntington's disease
  • Balance risks of depression and suicidality with the clinical need for control of chorea when considering the use of tetrabenazine
  • Monitor patients for emergence or worsening of depression, suicidality or unusual changes in behavior
  • Inform patients, caregivers and families of the risk of depression and suicidality and instruct to report behaviours of concern promptly to the treating physician
  • Exercise caution when treating patients with a history of depression or prior suicide attempts or ideation
  • Tetrabenazine is contraindicated in patients who are actively suicidal and in patients with untreated or inadequately treated depression


Pharmacology
The precise mechanism of action of tetrabenazine is unknown. Its anti-chorea effect is believed to be due to a reversible depletion of monoamines such as , , , and from nerve terminals. Tetrabenazine reversibly inhibits vesicular monoamine transporter 2 (VMAT2), resulting in decreased uptake of monoamines into synaptic vesicles, as well as depletion of monoamine storage.


Research

Animal model of motivational dysfunction
Tetrabenazine is used in the only of .
(2025). 9780444641670
The drug results in selective depletion of dopamine at low doses of 0.25 to 1.0mg/kg and induces a low-effort bias in effort-based decision-making tasks at these doses. It has been found to reduce or nucleus accumbens dopamine levels by 57 to 75% at a dose of 0.75–1.0mg/kg in rats. In contrast, levels of serotonin and norepinephrine are only reduced by up to 15 to 30% at this dosage. A 10-fold higher dosage of 10mg/kg is needed to decrease serotonin levels as much as the reduction in dopamine levels at 1mg/kg. The low-effort bias of systemic administration of tetrabenazine also occurs when it is injected directly into the nucleus accumbens but not the overlying medial neostriatum (i.e., ). Dopamine D1 receptor antagonists like and dopamine D2 receptor antagonists like have similar amotivational effects as tetrabenazine in animals.

A number of pro-motivational drugs have been found to reverse the amotivational effects of tetrabenazine. These include the dopamine releasing agent , the dopamine reuptake inhibitors , , , , PRX-14040, and MRZ-9547, and the and catecholaminergic activity enhancer . Selegiline shows a complicated dose–response curve in its efficacy in the model. In contrast to the preceding agents, many , including selective serotonin reuptake inhibitors (SSRIs) like and , the norepinephrine reuptake inhibitors (NRIs) and , the selective , and the non-selective monoamine oxidase inhibitor , are ineffective in reversing tetrabenazine-induced amotivational symptoms. SSRIs and NRIs actually induced further motivational impairments at high doses.

A retrospective longitudinal study in a cohort of 23 children with dyskinetic cerebral palsy was conducted where they were treated with tetrabenazine. Results showed significant improvement in movement disorders over time. The study supports tetrabenzine's potential for DCP treatment and shows that the MD-CRS 4-18 scale is a tool for tracking progress in future clinical trials.


See also


External links

Page 1 of 1
1
Page 1 of 1
1

Account

Social:
Pages:  ..   .. 
Items:  .. 

Navigation

General: Atom Feed Atom Feed  .. 
Help:  ..   .. 
Category:  ..   .. 
Media:  ..   .. 
Posts:  ..   ..   .. 

Statistics

Page:  .. 
Summary:  .. 
1 Tags
10/10 Page Rank
5 Page Refs
1s Time